Skip to main content
. 2022 Aug 27;4(11):100574. doi: 10.1016/j.jhepr.2022.100574

Table 1.

Baseline characteristics of 354 people with compensated NAFLD cirrhosis included in the study.

Overall n = 354 Without prior decompensations n = 271 With prior decompensations n = 83 p value
Age, mean years (SD) 67.3 (9.6) 66.9 (9.2) 68.8 (10.5) 0.11
Females, n (%) 171 (48.3) 132 (48.7) 39 (47.0) 0.78
Tobacco use, n (%) 38 (10.8) 27 (10.1) 11 (13.3) 0.41
Alcohol use, n (%) 76 (21.5) 60 (22.1) 16 (19.3) 0.57
BMI, median kg/m2 (IQR) 31.2 (27.6-35.1) 31.8 (27.8-35.3) 30.2 (26.9-32.9) 0.023
BMI ≥25 kg/m2, n (%) 302 (92.9) 240 (94.1) 62 (88.6) 0.10
BMI ≥30 kg/m2, n (%) 188 (57.8) 150 (58.8) 38 (54.3) 0.49
Arterial hypertension, n (%) 251 (70.9) 193 (71.2) 58 (69.9) 0.81
T2D, n (%) 258 (72.9) 196 (72.3) 62 (74.7) 0.67
Dyslipidaemia, n (%) 181 (51.1) 142 (52.4) 39 (47.0) 0.38
Previous stroke, n (%) 16 (4.5) 14 (5.2) 2 (2.4) 0.29
Previous ischemic heart disease, n (%) 35 (9.9) 26 (9.6) 9 (10.8) 0.73
Child-Pugh score
A/B/C, n (%) 287 (86.9)/40 (12.1)/3 (1.0)
Liver stiffness, mean kPa (SD)∗∗ 23.6 (14.8) 22.9 (13.8) 33.9 (25.4) 0.10
CAP, mean dB/m (SD)∗∗∗ 307.0 (58.0) 308.1 (57.6) 281.3 (77.6) 0.43

Hypertension: ≥140/90 mmHg or requiring treatment; type 2 diabetes: as a fasting plasma glucose ≥126 mg/dl or a non-fasting plasma glucose ≥180 mg/dl or requiring treatment.; dyslipidemia: serum triglycerides ≥150 mg/dl and/or total cholesterol >200 mg/dl, LDL >130 mg/dl, HDL<40 mg/dl in men and <50 mg/dl in women or requiring treatment.

Continuous variables were compared using t test or Wilcoxon rank-sum, depending on the normality of their distribution. Categorical variables were compared using the chi-square test. A p <0.05 was considered statistically significant.

CAP, controlled attenuation parameter; T2D, type 2 diabetes.

Alcohol intake was defined as <20 g/day and <30 g/day for women and men, respectively.

∗∗

Data available in 83 individuals.

∗∗∗

Data available in 75 individuals.